IN2014DN11063A - - Google Patents
Info
- Publication number
- IN2014DN11063A IN2014DN11063A IN11063DEN2014A IN2014DN11063A IN 2014DN11063 A IN2014DN11063 A IN 2014DN11063A IN 11063DEN2014 A IN11063DEN2014 A IN 11063DEN2014A IN 2014DN11063 A IN2014DN11063 A IN 2014DN11063A
- Authority
- IN
- India
- Prior art keywords
- polyester
- polyethylene glycol
- copolymer containing
- active principle
- bupivacaine
- Prior art date
Links
- 239000002202 Polyethylene glycol Substances 0.000 abstract 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
- 229920000728 polyester Polymers 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 abstract 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- 229960003150 bupivacaine Drugs 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 229930182912 cyclosporin Natural products 0.000 abstract 1
- 229920000359 diblock copolymer Polymers 0.000 abstract 1
- 238000012377 drug delivery Methods 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 229960004400 levonorgestrel Drugs 0.000 abstract 1
- 229960002985 medroxyprogesterone acetate Drugs 0.000 abstract 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- 229920000428 triblock copolymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261665192P | 2012-06-27 | 2012-06-27 | |
| PCT/IB2013/001547 WO2014001904A1 (en) | 2012-06-27 | 2013-06-27 | Biodegradable drug delivery for hydrophobic compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN11063A true IN2014DN11063A (enExample) | 2015-09-25 |
Family
ID=49117888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN11063DEN2014 IN2014DN11063A (enExample) | 2012-06-27 | 2013-06-27 |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20150150987A1 (enExample) |
| EP (1) | EP2866837B1 (enExample) |
| JP (1) | JP6134788B2 (enExample) |
| KR (1) | KR102189442B1 (enExample) |
| CN (1) | CN104582733B (enExample) |
| AU (1) | AU2013282891B2 (enExample) |
| BR (1) | BR112014031773B1 (enExample) |
| CA (1) | CA2877083C (enExample) |
| CL (1) | CL2014003531A1 (enExample) |
| CO (1) | CO7160098A2 (enExample) |
| CR (1) | CR20140581A (enExample) |
| CU (1) | CU24287B1 (enExample) |
| EA (1) | EA031522B1 (enExample) |
| ES (1) | ES2938586T3 (enExample) |
| IL (1) | IL236472B (enExample) |
| IN (1) | IN2014DN11063A (enExample) |
| MA (1) | MA37809B1 (enExample) |
| MX (1) | MX353280B (enExample) |
| SG (1) | SG11201408658PA (enExample) |
| TN (1) | TN2014000520A1 (enExample) |
| UA (1) | UA113549C2 (enExample) |
| WO (2) | WO2014001905A1 (enExample) |
| ZA (1) | ZA201409291B (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| BR112014012444B1 (pt) | 2011-11-23 | 2021-12-14 | Therapeuticsmd, Inc | Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| UA119324C2 (uk) * | 2013-04-02 | 2019-06-10 | Теміс Медікер Лімітед | Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні |
| JP6539274B2 (ja) | 2013-08-12 | 2019-07-03 | ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド | 押出成形された即放性乱用抑止性丸剤 |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| JP6640725B2 (ja) | 2014-01-27 | 2020-02-05 | セントレ ナショナル デ ラ レチャーチェ シャーティフィック | ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す |
| CA2947767A1 (en) | 2014-05-22 | 2015-11-26 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| WO2016054197A1 (en) * | 2014-09-30 | 2016-04-07 | University Of Tennessee Research Foundation | In situ gelling form for long-acting drug delivery |
| US20160106737A1 (en) | 2014-10-20 | 2016-04-21 | Pharmaceutical Manufacturing Research Services, Inc. | Extended Release Abuse Deterrent Liquid Fill Dosage Form |
| FR3027522B1 (fr) | 2014-10-27 | 2016-12-09 | I Ceram | Composition poreuse chargee en principe actif |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| AU2016355236C1 (en) * | 2015-11-16 | 2022-09-22 | Medincell | A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue |
| WO2017173071A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| US11766400B2 (en) * | 2016-10-24 | 2023-09-26 | Yale University | Biodegradable contraceptive implants |
| JP2020511483A (ja) | 2017-03-20 | 2020-04-16 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 徐放性オランザピン製剤 |
| SI3655017T1 (sl) | 2017-07-17 | 2025-06-30 | Medincell S.A. | Farmacevtski sestavki |
| GB2568526A (en) | 2017-11-20 | 2019-05-22 | Rebio Tech Oy | Composition |
| CN108078911A (zh) * | 2017-12-08 | 2018-05-29 | 复旦大学 | 用于动物避孕的热致水凝胶缓释兽药注射剂及其制备方法 |
| JP7482874B2 (ja) * | 2018-08-22 | 2024-05-14 | バカイン バイオセラピューティクス， リミテッド | シクロスポリン組成物および使用方法 |
| GB201900258D0 (en) * | 2019-01-08 | 2019-02-27 | Medincell | Pharmaceutical composition |
| EP4027973B8 (en) | 2019-09-13 | 2025-12-17 | Medincell S.A. | Drug delivery formulations |
| CN111700876A (zh) * | 2020-03-12 | 2020-09-25 | 上海市肿瘤研究所 | 一种治疗系统性红斑狼疮的载药递送给药系统及其制备方法 |
| WO2022129417A1 (en) | 2020-12-16 | 2022-06-23 | Medincell | Methods and compositions for the prophylactic treatment of sars-cov-2 virus (covid-19) |
| FI20215186A1 (en) | 2021-02-19 | 2022-08-20 | Rebio Tech Oy | Compositions for ophthalmic treatment |
| AU2022236485A1 (en) | 2021-03-17 | 2023-08-24 | Medincell S. A. | Long acting injectable formulation comprising risperidone and biodegradable polymers |
| AU2022264844A1 (en) * | 2021-04-30 | 2023-11-23 | Medincell Sa | New formulation |
| WO2025081046A1 (en) * | 2023-10-11 | 2025-04-17 | The Brigham And Women's Hospital, Inc. | Ultra-high drug loading injectable drug suspension of hydrophobic drugs for long-term drug delivery |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8416234D0 (en) * | 1984-06-26 | 1984-08-01 | Ici Plc | Biodegradable amphipathic copolymers |
| HU222501B1 (hu) * | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
| US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
| KR0180334B1 (ko) * | 1995-09-21 | 1999-03-20 | 김윤 | 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법 |
| FR2741628B1 (fr) | 1995-11-29 | 1998-02-06 | Centre Nat Rech Scient | Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| WO2002085337A1 (en) | 2001-04-20 | 2002-10-31 | The University Of British Columbia | Micellar drug delivery systems for hydrophobic drugs |
| CN100408099C (zh) * | 2000-11-09 | 2008-08-06 | 阿斯特拉曾尼卡有限公司 | 含有嵌段共聚物的口服药物组合物 |
| KR100446101B1 (ko) * | 2000-12-07 | 2004-08-30 | 주식회사 삼양사 | 수난용성 약물의 서방성 제형 조성물 |
| US6592899B2 (en) | 2001-10-03 | 2003-07-15 | Macromed Incorporated | PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water |
| US7649023B2 (en) * | 2002-06-11 | 2010-01-19 | Novartis Ag | Biodegradable block copolymeric compositions for drug delivery |
| WO2005000278A1 (en) * | 2003-06-26 | 2005-01-06 | Mediolanum Pharmaceuticals Ltd. | Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof |
| US20050112170A1 (en) * | 2003-11-20 | 2005-05-26 | Hossainy Syed F. | Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same |
| WO2007019439A2 (en) * | 2005-08-04 | 2007-02-15 | Angiotech International Ag | Block copolymer compositions and uses thereof |
| CN101273963A (zh) * | 2007-11-22 | 2008-10-01 | 山东蓝金生物工程有限公司 | 一种含激素类抗癌药的温控缓释注射剂 |
| US8846068B2 (en) * | 2008-04-18 | 2014-09-30 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising a local anesthetic |
| EP2359860B1 (en) * | 2008-11-21 | 2014-08-06 | Samyang Biopharmaceuticals Corporation | Polymer micelle composition for treatment of resistant cancer cells |
| CN101810560B (zh) * | 2009-02-20 | 2013-07-10 | 北京大学 | 环孢a聚合物胶束组合物 |
| AU2011350898B2 (en) * | 2010-12-29 | 2016-09-08 | Medincell | Biodegradable drug delivery compositions |
-
2013
- 2013-06-27 MX MX2014015902A patent/MX353280B/es active IP Right Grant
- 2013-06-27 CA CA2877083A patent/CA2877083C/en active Active
- 2013-06-27 IN IN11063DEN2014 patent/IN2014DN11063A/en unknown
- 2013-06-27 CN CN201380044335.7A patent/CN104582733B/zh active Active
- 2013-06-27 EP EP13758976.8A patent/EP2866837B1/en active Active
- 2013-06-27 ES ES13758976T patent/ES2938586T3/es active Active
- 2013-06-27 WO PCT/IB2013/001549 patent/WO2014001905A1/en not_active Ceased
- 2013-06-27 SG SG11201408658PA patent/SG11201408658PA/en unknown
- 2013-06-27 AU AU2013282891A patent/AU2013282891B2/en active Active
- 2013-06-27 MA MA37809A patent/MA37809B1/fr unknown
- 2013-06-27 CU CUP2014000148A patent/CU24287B1/xx unknown
- 2013-06-27 KR KR1020157002309A patent/KR102189442B1/ko active Active
- 2013-06-27 EA EA201492172A patent/EA031522B1/ru not_active IP Right Cessation
- 2013-06-27 US US14/410,994 patent/US20150150987A1/en not_active Abandoned
- 2013-06-27 JP JP2015519379A patent/JP6134788B2/ja active Active
- 2013-06-27 UA UAA201413827A patent/UA113549C2/uk unknown
- 2013-06-27 WO PCT/IB2013/001547 patent/WO2014001904A1/en not_active Ceased
- 2013-06-27 BR BR112014031773-9A patent/BR112014031773B1/pt active IP Right Grant
-
2014
- 2014-12-15 TN TN2014000520A patent/TN2014000520A1/fr unknown
- 2014-12-16 CR CR20140581A patent/CR20140581A/es unknown
- 2014-12-17 ZA ZA2014/09291A patent/ZA201409291B/en unknown
- 2014-12-24 CL CL2014003531A patent/CL2014003531A1/es unknown
- 2014-12-25 IL IL236472A patent/IL236472B/en active IP Right Grant
- 2014-12-26 CO CO14284191A patent/CO7160098A2/es unknown
-
2018
- 2018-07-30 US US16/049,580 patent/US20190160171A1/en not_active Abandoned
-
2019
- 2019-11-22 US US16/692,487 patent/US20200085958A1/en not_active Abandoned
-
2020
- 2020-09-18 US US17/025,826 patent/US20210008216A1/en not_active Abandoned
-
2022
- 2022-05-19 US US17/748,464 patent/US20220354956A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN11063A (enExample) | ||
| TN2013000267A1 (en) | Biodegradable drug delivery compositions | |
| WO2012021715A3 (en) | Stable formulations of linaclotide | |
| WO2012075362A3 (en) | Chemokine cxcr4 receptor modulators and used related thereto | |
| HK1213174A1 (zh) | 穩定的含水依那西普製劑 | |
| WO2011101863A3 (en) | Extended release pharmaceutical compositions of lacosamide | |
| HK1213779A1 (zh) | 用於立即和延长释放的组合物 | |
| PL2560612T3 (pl) | Sposób wytwarzania kompozycji farmaceutycznych do doustnego podawania zawierających jeden lub więcej składników czynnych oraz kompozycje je zawierające | |
| EP2643009A4 (en) | COMPOSITION FOR THE RELEASE OF BIODEGRADABLE ACTIVE SUBSTANCES | |
| UA102120C2 (ru) | Пероральная форма дозирования бендамустина | |
| IN2013MU03658A (enExample) | ||
| WO2012085284A3 (en) | High drug load pharmaceutical formulations comprising dronedarone and its pharmaceutically acceptable salts | |
| MD20150053A2 (ro) | Produs de comicronizare cu conţinut de acetat de ulipristal | |
| WO2011142731A3 (en) | Formulations comprising a third generation cephalosporin and clavulanic acid | |
| JO3587B1 (ar) | أشكال جرعات بينداموستين عن طريق الفم | |
| WO2012147101A3 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| WO2013112806A3 (en) | Transdermal hormone delivery | |
| WO2011039675A3 (en) | Latrepirdine transdermal therapeutic dosage forms | |
| TN2011000352A1 (en) | New combination of active ingredients containing a non steroidal anti inflammatory drug and a colchicoside derivative | |
| UA97076C2 (ru) | Мазь противовоспалительная на основе сульфаниламида |